The Quantellect read.As of Nov 19, 2026, 17 active firms cover Cytokinetics Inc: 17 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $84.00 to $140.00, a moderate spread. The average target of $108.44 sits 111% above the current $51.31. The rating mix has stayed broadly stable, with Buy-side ratings easing from 18 to 17 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.28 next quarter toward $-4.23 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS17 active firms
Buy
Strong Buy00%
Buy17100%
Neutral00%
Sell00%
Strong Sell00%
Based on 17 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$108.44
+111.3% upside
Average target across 16 active firms as of Nov 19, 2026 vs $51.31 current
Highest Target$140.00
Average Target$108.44
Lowest Target$84.00
Detailed analyst forecasts for CYTK
Showing 1–19 of 19 named analysts shown · 17 active firms in the rating projection
As of Nov 19, 2026, 17 of 17 active firms rate CYTK a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CYTK EPS & revenue forecast
EPS · NEXT QUARTER
$-1.28
Range $-1.55 – $-0.73 · 6 analysts · -23% YoY
Next period, 6 analysts expect Cytokinetics Inc to earn $-1.28 a share (range $-1.55 – $-0.73), versus $-1.67 a year earlier. Full-year consensus is $-5.76, growing to $-4.23 the year after.
REVENUE · NEXT QUARTER
$75.3M
Range $56.4M – $95.4M · 6 analysts · +289% YoY
Revenue is expected to reach $75.3M (range $56.4M – $95.4M), +289.0% year-over-year. Full-year consensus is $164.6M, rising to $443.1M next year.
Top analysts covering Cytokinetics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CYTK.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #10
Buy
$103.00+100.7% to target
Overall win rate
64%
+ Follow
#2
Leonid Timashev
RBC Capital · Rank #27
Buy
$113.00+120.2% to target
Overall win rate
52%
+ Follow
#3
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$146.00+184.5% to target
Overall win rate
49%
+ Follow
#4
Jason Butler
JMP Securities · Rank #62
Buy
$110.00+114.4% to target
Overall win rate
49%
+ Follow
#5
Paul Choi
Goldman Sachs · Rank #110
Buy
$105.00+104.6% to target
Overall win rate
52%
+ Follow
CYTK stock forecast FAQ
What is CYTK's average 12-month price target?+
The 16 active firms with a live target average $108.44 for Cytokinetics Inc over the next 12 months, ranging from a $140.00 high to a $84.00 low, as of Nov 19, 2026.
Is CYTK stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 17 active firms as of Nov 19, 2026, 17 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CYTK?+
The Street-high target is $140.00 (HC Wainwright & Co.), and the Street-low is $84.00 (Leerink Partners). The average of all 16 active-firm targets is $108.44.
How many active Wall Street firms cover CYTK?+
17 active firms have a recognized rating on Cytokinetics Inc as of Nov 19, 2026, and 16 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CYTK?+
Among analysts who currently cover CYTK, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #10). Their current call is Buy with a $103.00 target.
What is Cytokinetics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.28 per share (range $-1.55 – $-0.73) across 6 analysts. Full-year EPS is projected at $-5.76, rising to $-4.23 the following year.
How much revenue is Cytokinetics Inc expected to report next quarter?+
Consensus revenue is $75.3M (range $56.4M – $95.4M). Full-year revenue is projected at $164.6M, growing to $443.1M next year.
Have analysts been upgrading or downgrading CYTK lately?+
As of Nov 19, 2026, 17 of 17 active firms rate CYTK a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CYTK calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.